{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Endometrium&page=2", "query": { "condition": "Adenocarcinoma of Endometrium", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+Endometrium&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T12:42:48.962Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006011", "title": "Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation", "Endometrial Serous Adenocarcinoma", "Stage III Uterine Corpus Cancer" ], "interventions": [ { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 659, "start_date": "2000-07", "completion_date": null, "has_results": true, "last_update_posted_date": "2015-05-19", "last_synced_at": "2026-06-11T12:42:48.962Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006011" }, { "nct_id": "NCT02065687", "title": "Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IIIA Uterine Corpus Cancer AJCC v7", "Stage IIIB Uterine Corpus Cancer AJCC v7", "Stage IIIC Uterine Corpus Cancer AJCC v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Stage IVA Uterine Corpus Cancer AJCC v7", "Stage IVB Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Metformin Hydrochloride", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 469, "start_date": "2014-03-17", "completion_date": "2023-09-13", "has_results": true, "last_update_posted_date": "2021-09-30", "last_synced_at": "2026-06-11T12:42:48.962Z", "location_count": 431, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065687" }, { "nct_id": "NCT01225887", "title": "Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Squamous Cell Carcinoma", "Endometrial Transitional Cell Carcinoma", "Endometrial Undifferentiated Carcinoma", "Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm", "Recurrent Uterine Corpus Carcinoma" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 37, "start_date": "2011-10", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-10-09", "last_synced_at": "2026-06-11T12:42:48.962Z", "location_count": 59, "location_summary": "Burbank, California • Aurora, Colorado • Hartford, Connecticut + 40 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT01225887" }, { "nct_id": "NCT03914612", "title": "Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Clear Cell Adenocarcinoma", "Endometrial Dedifferentiated Carcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Recurrent Endometrial Adenocarcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Endometrial Dedifferentiated Carcinoma", "Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Endometrial Mixed Cell Adenocarcinoma", "Recurrent Endometrial Serous Adenocarcinoma", "Recurrent Endometrial Undifferentiated Carcinoma", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 813, "start_date": "2019-08-22", "completion_date": "2026-09-26", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-06-11T12:42:48.962Z", "location_count": 370, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 272 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03914612" }, { "nct_id": "NCT01184053", "title": "Trisenox® in Women With Metastatic Endometrial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Carcinoma" ], "interventions": [ { "name": "Arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2010-03", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-06-11T12:42:48.962Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01184053" }, { "nct_id": "NCT05325866", "title": "A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Bemarituzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 260, "start_date": "2022-09-23", "completion_date": "2026-01-28", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-06-11T12:42:48.962Z", "location_count": 10, "location_summary": "Duarte, California • Orange, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05325866" }, { "nct_id": "NCT00285415", "title": "A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Endometrial Adenocarcinoma, Stage III A, B, C" ], "interventions": [ { "name": "Docetaxel and Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carilion Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 46, "start_date": "2005-04", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2021-02-05", "last_synced_at": "2026-06-11T12:42:48.962Z", "location_count": 2, "location_summary": "Greenville, South Carolina • Roanoke, Virginia", "locations": [ { "city": "Greenville", "state": "South Carolina" }, { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00285415" }, { "nct_id": "NCT00064025", "title": "Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation", "Recurrent Uterine Corpus Carcinoma", "Stage I Uterine Corpus Cancer", "Stage II Uterine Corpus Cancer", "Stage III Uterine Corpus Cancer", "Stage IV Uterine Corpus Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Medroxyprogesterone", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 75, "start_date": "2004-04", "completion_date": null, "has_results": true, "last_update_posted_date": "2016-04-11", "last_synced_at": "2026-06-11T12:42:48.962Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064025" }, { "nct_id": "NCT00006027", "title": "Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": null, "start_date": "2000-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-06-11T12:42:48.962Z", "location_count": 28, "location_summary": "Los Angeles, California • Los Gatos, California • Orange, California + 25 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Gatos", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006027" }, { "nct_id": "NCT02549209", "title": "Pembro/Carbo/Taxol in Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Endometrial Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daniela Matei, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 46, "start_date": "2017-08-22", "completion_date": "2022-02-10", "has_results": true, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-06-11T12:42:48.962Z", "location_count": 6, "location_summary": "Mesa, Arizona • Chicago, Illinois • Lake Forest, Illinois + 3 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02549209" } ] }